Patient demographics by group
| . | KSCTG TA-TMA N = 121 . | OMS721-TMA-001 N = 28 . | EAP N = 49 . | OMS721-TMA-001 + EAP N = 77 . |
|---|---|---|---|---|
| Age, y | ||||
| Median (IQR) | 52 (40-61) | 48 (36.5-58.0) | 55.4 (29.8-63.4) | 49 (33-62) |
| Min, max | 17, 74 | 22, 68 | 16, 71.7 | 16, 71.7 |
| Sex, n (%) | ||||
| Male | 73 (60.3) | 20 (71.4) | 25 (51.0) | 45 (58.4) |
| Female | 48 (39.7) | 8 (28.6) | 24 (49.0) | 32 (41.6) |
| Time from HCT to TMA diagnosis, d | ||||
| n | 121 | 28 | 45 | 73 |
| Median | 35 | 119 | 94.5 | 85 |
| Min, max | 3, 410 | 33, 444 | 0, 1042 | 0, 1042 |
| Related donor, n (%) | ||||
| Related | 33 (27.3) | 12 (42.9) | 17 (34.7) | 29 (37.7) |
| Unrelated | 88 (72.7) | 16 (57.1) | 18 (36.7) | 34 (44.2) |
| Unknown | 0 | 0 | 16 (32.7) | 16 (20.8) |
| Cell source, n (%) | ||||
| BM | 53 (43.8) | 6 (21.4) | 5 (10.2) | 11 (14.3) |
| PBSC | 21 (17.4) | 20 (71.4) | 28 (57.1) | 48 (62.3) |
| Unrelated CB | 47 (38.8) | 2 (7.1) | 2 (4.1) | 4 (5.2) |
| Unknown | 0 | 0 | 16 (32.7) | 16 (20.8) |
| HCT conditioning regimen, n (%) | ||||
| Reduced intensity conditioning | 59 (48.8) | 15 (53.5) | 20 (40.8) | 36 (46.8) |
| Myeloablative conditioning | 62 (51.2) | 13 (46.4) | 15 (30.6) | 27 (35.1) |
| Unknown | 0 | 0 | 9 (18.4) | 9 (11.7) |
| Narsoplimab treatment,∗median (min, max) | ||||
| No. of doses | NA | 8 (2, 8) | 10 (1, 54) | ND |
| Duration of treatment, wk | NA | 8 (2, 16.4) | 6 (0.1, 31.7) | ND |
| . | KSCTG TA-TMA N = 121 . | OMS721-TMA-001 N = 28 . | EAP N = 49 . | OMS721-TMA-001 + EAP N = 77 . |
|---|---|---|---|---|
| Age, y | ||||
| Median (IQR) | 52 (40-61) | 48 (36.5-58.0) | 55.4 (29.8-63.4) | 49 (33-62) |
| Min, max | 17, 74 | 22, 68 | 16, 71.7 | 16, 71.7 |
| Sex, n (%) | ||||
| Male | 73 (60.3) | 20 (71.4) | 25 (51.0) | 45 (58.4) |
| Female | 48 (39.7) | 8 (28.6) | 24 (49.0) | 32 (41.6) |
| Time from HCT to TMA diagnosis, d | ||||
| n | 121 | 28 | 45 | 73 |
| Median | 35 | 119 | 94.5 | 85 |
| Min, max | 3, 410 | 33, 444 | 0, 1042 | 0, 1042 |
| Related donor, n (%) | ||||
| Related | 33 (27.3) | 12 (42.9) | 17 (34.7) | 29 (37.7) |
| Unrelated | 88 (72.7) | 16 (57.1) | 18 (36.7) | 34 (44.2) |
| Unknown | 0 | 0 | 16 (32.7) | 16 (20.8) |
| Cell source, n (%) | ||||
| BM | 53 (43.8) | 6 (21.4) | 5 (10.2) | 11 (14.3) |
| PBSC | 21 (17.4) | 20 (71.4) | 28 (57.1) | 48 (62.3) |
| Unrelated CB | 47 (38.8) | 2 (7.1) | 2 (4.1) | 4 (5.2) |
| Unknown | 0 | 0 | 16 (32.7) | 16 (20.8) |
| HCT conditioning regimen, n (%) | ||||
| Reduced intensity conditioning | 59 (48.8) | 15 (53.5) | 20 (40.8) | 36 (46.8) |
| Myeloablative conditioning | 62 (51.2) | 13 (46.4) | 15 (30.6) | 27 (35.1) |
| Unknown | 0 | 0 | 9 (18.4) | 9 (11.7) |
| Narsoplimab treatment,∗median (min, max) | ||||
| No. of doses | NA | 8 (2, 8) | 10 (1, 54) | ND |
| Duration of treatment, wk | NA | 8 (2, 16.4) | 6 (0.1, 31.7) | ND |
BM, bone marrow; CB, cord blood; IQR, interquartile range; max, maximum; min, minimum; NA, not applicable; ND, not determined; PBSC, peripheral blood stem cells.
Narsoplimab treatment is reported separately for OMS721-TMA-001 and the EAP. This was not calculated for the pooled population.